Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mocertatug rezetecan - Shanghai Hansoh Biomedical

Next Previous
Drug Profile

Mocertatug rezetecan - Shanghai Hansoh Biomedical

Alternative Names: GSK-5733584; HS-20089; Mo-Rez - Shanghai Hansoh Biomedical

Latest Information Update: 10 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai Hansoh Biomedical
  • Developer GSK; Shanghai Hansoh Biomedical
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 06 Jul 2026 GSK plans phase III BEHOLD-Endometrial02 trial for Endometrial cancer (Late-stage disease, Recurrent, Combination therapy) in September 2026 (Parenteral) (NCT07684599) (CTIS2025-523363-37)
  • 06 Jul 2026 GSK plans phase III BEHOLD-Ovarian02 trial for Ovarian Cancer (Second-line therapy or greater, Recurrent, Combination therapy) in September (Parenteral) (NCT07684612) (CTIS2025-523366-24)
  • 18 Jun 2026 Phase-III clinical trials in Fallopian tube cancer (Second-line therapy or greater, Late-stage disease) in Japan, Canada, Australia (Parenteral) (NCT07286266)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top